
Sign up to save your podcasts
Or
Recently, we headed to Washington D.C. for a State of the Science Summit on Non–Small Cell Lung Cancer. Topics ranged from determining optimal strategies for molecular interrogation in NSCLC to the emergence of rare, targetable biomarkers—such as MET, RET, and NTRK. Presentations also focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.
4.2
2121 ratings
Recently, we headed to Washington D.C. for a State of the Science Summit on Non–Small Cell Lung Cancer. Topics ranged from determining optimal strategies for molecular interrogation in NSCLC to the emergence of rare, targetable biomarkers—such as MET, RET, and NTRK. Presentations also focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.
38,689 Listeners
902 Listeners
8,659 Listeners
113 Listeners
10 Listeners
493 Listeners
58 Listeners
3,332 Listeners
185 Listeners
43 Listeners
27 Listeners
56 Listeners
169 Listeners
39 Listeners
54 Listeners